X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs NOVARTIS - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA NOVARTIS DISHMAN PHARMA/
NOVARTIS
 
P/E (TTM) x 25.1 347.8 7.2% View Chart
P/BV x 3.3 17.1 19.5% View Chart
Dividend Yield % 0.7 1.7 39.4%  

Financials

 DISHMAN PHARMA   NOVARTIS
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
NOVARTIS
Mar-16
DISHMAN PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs374982 38.1%   
Low Rs129556 23.2%   
Sales per share (Unadj.) Rs197.8252.9 78.2%  
Earnings per share (Unadj.) Rs21.262.1 34.1%  
Cash flow per share (Unadj.) Rs34.763.3 54.9%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.81.3 61.1%  
Book value per share (Unadj.) Rs179.9363.6 49.5%  
Shares outstanding (eoy) m80.6931.96 252.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.0 41.8%   
Avg P/E ratio x11.912.4 95.9%  
P/CF ratio (eoy) x7.212.2 59.6%  
Price / Book Value ratio x1.42.1 66.1%  
Dividend payout %9.416.1 58.6%   
Avg Mkt Cap Rs m20,30624,580 82.6%   
No. of employees `0000.80.8 110.2%   
Total wages/salary Rs m5,3551,801 297.3%   
Avg. sales/employee Rs Th19,252.710,748.9 179.1%   
Avg. wages/employee Rs Th6,459.52,395.2 269.7%   
Avg. net profit/employee Rs Th2,064.12,641.1 78.2%   
INCOME DATA
Net Sales Rs m15,9618,083 197.5%  
Other income Rs m265829 32.0%   
Total revenues Rs m16,2268,913 182.1%   
Gross profit Rs m4,103234 1,752.0%  
Depreciation Rs m1,09137 2,971.7%   
Interest Rs m9442 52,466.7%   
Profit before tax Rs m2,3341,025 227.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m117 6.6%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m624752 82.9%   
Profit after tax Rs m1,7111,986 86.2%  
Gross profit margin %25.72.9 887.3%  
Effective tax rate %26.773.4 36.4%   
Net profit margin %10.724.6 43.6%  
BALANCE SHEET DATA
Current assets Rs m11,01812,678 86.9%   
Current liabilities Rs m9,5172,433 391.2%   
Net working cap to sales %9.4126.7 7.4%  
Current ratio x1.25.2 22.2%  
Inventory Days Days11033 337.9%  
Debtors Days Days3522 154.9%  
Net fixed assets Rs m16,30469 23,560.8%   
Share capital Rs m161160 101.0%   
"Free" reserves Rs m12,90711,460 112.6%   
Net worth Rs m14,51611,621 124.9%   
Long term debt Rs m4,1890-   
Total assets Rs m29,80514,400 207.0%  
Interest coverage x3.5570.5 0.6%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.6 95.4%   
Return on assets %8.913.8 64.5%  
Return on equity %11.817.1 69.0%  
Return on capital %17.523.6 74.4%  
Exports to sales %24.80.7 3,328.3%   
Imports to sales %3.718.6 20.1%   
Exports (fob) Rs m3,95660 6,571.8%   
Imports (cif) Rs m5961,503 39.7%   
Fx inflow Rs m4,952186 2,657.8%   
Fx outflow Rs m6971,821 38.3%   
Net fx Rs m4,255-1,635 -260.3%   
CASH FLOW
From Operations Rs m2,7862,531 110.1%  
From Investments Rs m-1,529-8,270 18.5%  
From Financial Activity Rs m-941-386 244.0%  
Net Cashflow Rs m316-6,125 -5.2%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.7 2.0 185.0%  
FIIs % 12.7 1.6 793.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 21.5 102.8%  
Shareholders   46,261 41,647 111.1%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   PIRAMAL ENTERPRISES  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  ABBOTT INDIA  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS